Chemical‐Driven Outflow of Dissociated Amyloid Burden from Brain to Blood
Abstract Amyloid‐β (Aβ) deposition in the brain is a primary biomarker of Alzheimer's disease (AD) and Aβ measurement for AD diagnosis mostly depends on brain imaging and cerebrospinal fluid analyses. Blood Aβ can become a reliable surrogate biomarker if issues of low concentration for conventi...
Main Authors: | Donghee Lee, Hyunjin Vincent Kim, Hye Yun Kim, YoungSoo Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-04-01
|
Series: | Advanced Science |
Subjects: | |
Online Access: | https://doi.org/10.1002/advs.202104542 |
Similar Items
-
Immunization with amyloid-β using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology
by: Kevin A. DaSilva, et al.
Published: (2006-08-01) -
Impacts of CR1 genetic variants on cerebrospinal fluid and neuroimaging biomarkers in alzheimer’s disease
by: Xi-chen Zhu, et al.
Published: (2020-09-01) -
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)
by: Laurent Pradier, et al.
Published: (2018-11-01) -
Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort
by: Hyemin Jang, et al.
Published: (2021-10-01) -
Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
by: Julie K. Wisch, et al.
Published: (2023-01-01)